In gliomas, frequent IDH1/2 mutations are also observed but progress is even more limited, possibly owing to insufficient CNS penetration, an irreversible epigenetic landscape, or lack of tumor addiction to IDH1/2 mutations (134). Here, IDH1 is linked to central nervous system cancer.